<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4278">
  <stage>Registered</stage>
  <submitdate>30/01/2014</submitdate>
  <approvaldate>30/01/2014</approvaldate>
  <nctid>NCT02051608</nctid>
  <trial_identification>
    <studytitle>A Study of Gantenerumab in Participants With Mild Alzheimer Disease</studytitle>
    <scientifictitle>A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Efficacy and Safety Study of Gantenerumab in Patients With Mild Alzheimer's Disease; Part II: Open-Label Extension For Participating Patients</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2013-003390-95</secondaryid>
    <secondaryid>WN28745</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Alzheimer's Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Alzheimer's disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Dementias</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Florbetapir
Treatment: drugs - Gantenerumab
Treatment: drugs - Placebo

Experimental: Double-blind: Part 1 - Participants will receive either gantenerumab or placebo-matched to gantenerumab.

Experimental: Open - Label Extension: Part 2 - Participants will receive open label gantenerumab.

Experimental: PET Imaging Substudy - Participants will undergo PET imaging scans using the PET radioligand, a florbetapir F 18 injection.


Treatment: drugs: Florbetapir
IV injection of florbetapir [Amyvid] up to 370 mega Becquerel (MBq) (10 millicurie [mCi]) of florbetapir and imaging for up to 15 minutes per PET scan conducted at screening and on 3 subsequent time points per protocol

Treatment: drugs: Gantenerumab
Participants will receive gantenerumab as SC injection q4w up to Week 100

Treatment: drugs: Placebo
Participants will receive placebo as SC injection q4w up to Week 100q4w

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Mean Change From Baseline in Alzheimer's Disease Activity Scale-Cognitive subscale 13 (ADAS-Cog13) scores at Week 104</outcome>
      <timepoint>Baseline, Week 104</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Mean Change From Baseline in Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scores at week 104</outcome>
      <timepoint>Baseline, Week 104</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Part 2: Percentage of Participants with Adverse Events (AEs) or Serious Adverse Events (SAEs)</outcome>
      <timepoint>Baseline, Week 104</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>PET Imaging Substudy: Change From Baseline in Brain Amyloid Load Over Time Using Florbetapir</outcome>
      <timepoint>Baseline up to Week 104</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Total Tau (t-tau) in CSF at Week 104</outcome>
      <timepoint>Baseline, Week 104</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in phosphorylated tau [p-tau]in CSF at Week 104</outcome>
      <timepoint>Baseline, Week 104</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Abeta 1-42 levels in CSF at Week 104</outcome>
      <timepoint>Baseline, Week 104</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Hippocampal Volume, as Assessed by Magnetic Resonance Image (MRI) at Week 104</outcome>
      <timepoint>Baseline, Week 104</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Whole Brain Volume, as assessed by MRI at Week 104</outcome>
      <timepoint>Baseline, Week 104</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Cortical thickness, as assessed by MRI at Week 104</outcome>
      <timepoint>Baseline, Week 104</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Ventricular Volume, as Assessed by MRI at Week 104</outcome>
      <timepoint>Baseline, Week 104</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Clinical Dementia Rating Global Score (CDR-GS) at Week 104</outcome>
      <timepoint>Baseline, Week 104</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in CDR Sum of Boxes (SB) at Week 104</outcome>
      <timepoint>Baseline, Week 104</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Neuropsychiatric Inventory (NPI) Total Score at Week 104</outcome>
      <timepoint>Baseline, Week 104</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in NPI Domain Score at Week 104</outcome>
      <timepoint>Baseline, Week 104</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Mini Mental State Examination (MMSE) Total Score at Week 104</outcome>
      <timepoint>Baseline, Week 104</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety: Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs)</outcome>
      <timepoint>Baseline up to Week 152</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of Participants with anti-gantenerumab antibodies</outcome>
      <timepoint>Baseline up to Week 152</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Columbia - Suicide Severity Rating Scale (C-SSRS) Over Week 152</outcome>
      <timepoint>Baseline up to Week 152</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics: Apparent Oral Clearance (CL/F) of gantenerumab</outcome>
      <timepoint>Part 1: Predose (0 hour) at Baseline, Weeks 4, 8, 12, 24, 48, 72, 104, 116; Day 4; at unscheduled visits (up to Week 152) Part 2: Predose (0 hour) at Week 4, 12, 20, 104, 116; Weeks 53, 101; at unscheduled visits (up to Week 152)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics: Apparent Volume of Distribution (V/F) of gantenerumab</outcome>
      <timepoint>Part 1: Predose (0 hour) at Baseline, Weeks 4, 8, 12, 24, 48, 72, 104, 116; Day 4; at unscheduled visits (up to Week 152) Part 2: Predose (0 hour) at Week 4, 12, 20, 104, 116; Weeks 53, 101; at unscheduled visits (up to Week 152)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics: Maximum Observed Plasma Concentration (Cmax) of gantenerumab</outcome>
      <timepoint>Part 1: Predose (0 hour) at Baseline, Weeks 4, 8, 12, 24, 48, 72, 104, 116; Day 4; at unscheduled visits (up to Week 152) Part 2: Predose (0 hour) at Week 4, 12, 20, 104, 116; Weeks 53, 101; at unscheduled visits (up to Week 152)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics: Time to Reach Maximum Plasma Concentrations (Tmax) of gantenerumab</outcome>
      <timepoint>Part 1: Predose (0 hour) at Baseline, Weeks 4, 8, 12, 24, 48, 72, 104, 116; Day 4; at unscheduled visits (up to Week 152) Part 2: Predose (0 hour) at Week 4, 12, 20, 104, 116; Weeks 53, 101; at unscheduled visits (up to Week 152)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics: Minimum Observed Plasma Concentration (Cmin) of gantenerumab</outcome>
      <timepoint>Part 1: Predose (0 hour) at Baseline, Weeks 4, 8, 12, 24, 48, 72, 104, 116; Day 4; at unscheduled visits (up to Week 152) Part 2: Predose (0 hour) at Week 4, 12, 20, 104, 116; Weeks 53, 101; at unscheduled visits (up to Week 152)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics: Area Under Plasma Concentration (AUC) -Time Curve of gantenerumab</outcome>
      <timepoint>Part 1: Predose (0 hour) at Baseline, Weeks 4, 8, 12, 24, 48, 72, 104, 116; Day 4; at unscheduled visits (up to Week 152) Part 2: Predose (0 hour) at Week 4, 12, 20, 104, 116; Weeks 53, 101; at unscheduled visits (up to Week 152)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of Life - Change From Baseline in Alzheimer's Dementia (QoL-AD) Global Score at Week 104</outcome>
      <timepoint>Baseline, Week 104</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy: Change From Baseline in Symptom Guide Facilitated (GAS) at Week 104</outcome>
      <timepoint>Baseline, Week 104</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy: Change from Baseline in Dependence Scale (DS) at Week 104</outcome>
      <timepoint>Baseline, Week 104</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Efficacy: Change From Baseline in Resource Utilization Dementia-Lite (RUD - Life) Scale at Week 104</outcome>
      <timepoint>Baseline, Week 104</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change From Baseline in Zarit Caregiver Interview for Alzheimer's Disease (ZCI-AD) at Week 104</outcome>
      <timepoint>Baseline, Week 104</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Clinical Decline (as measured by Confirmed greater than of equal to [&gt;=] 2-point decline on MMSE, Loss of &gt;= 1 or 2 points on one or more ADL and I ADL, respectively)</outcome>
      <timepoint>Baseline up to Week 104</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change from Baseline in Clinical Composite Score (Prespecified Items From The ADAS-Cog, MMSE, and CDR) at Week 104</outcome>
      <timepoint>Baseline, Week 104</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Clinical diagnosis of probable mild Alzheimer disease (AD) based on National Institute
             of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related
             Disorders Association (NINCDS/ADRDA) criteria or major NCD based whether or not
             receiving AD approved medication

          -  Cerebral spinal fluid (CSF) result consistent with the presence of amyloid pathology

          -  Availability of a person ('caregiver') who in the investigator's judgment has frequent
             and sufficient contact with the participant, and is able to provide accurate
             information regarding the participant's cognitive and functional abilities

          -  Fluency in the language of the tests used at the study site

          -  Willingness and ability to complete all aspects of the study

          -  Adequate visual and auditory acuity, in the investigator's judgment, sufficient to
             perform the neuropsychological testing (eye glasses and hearing aids are permitted)

          -  If currently receiving approved medications for AD, the dosing regimen must have been
             stable for 3 months prior to screening

          -  Agreement not to participate in other research studies for the duration of this trial
             and its associated substudies

        PART 2 - All participants who have been randomized and are actively participating in the
        study are eligible for Part 2</inclusivecriteria>
    <inclusiveminage>50</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>90</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Dementia or neurocognitive disorder (NCD) due to a condition other than AD, including,
             but not limited to, frontotemporal dementia, Parkinson disease, dementia with Lewy
             bodies, Huntington disease, or vascular dementia

          -  History or presence of clinically evident vascular disease potentially affecting the
             brain that in the opinion of the investigator has the potential to affect cognitive
             function

          -  History or presence of stroke within the past 2 years or documented history of
             transient ischemic attack within the last 12 months

          -  History or presence of systemic autoimmune disorders potentially causing progressive
             neurologic disease with associated cognitive deficits

          -  History of schizophrenia, schizoaffective disorder, or bipolar disorder

          -  Alcohol and/or substance use disorder (according to the DSM-5) within the past 2 years
             (nicotine use is allowed)

          -  History or presence of atrial fibrillation

          -  Within the last 2 years, unstable or clinically significant cardiovascular disease
             (e.g., myocardial infarction, angina pectoris, cardiac failure New York Heart
             Association Class II or higher)

          -  Uncontrolled hypertension

          -  Chronic kidney disease

          -  Impaired hepatic function

        PET imaging substudy, in addition to above:

        - Prior participation in other research study or clinical care within the last year such
        that the total radiation exposure would exceed the local or national annual limits

        Part 2 Participants who have been discontinued from the study</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>27/03/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>1000</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>30/11/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA,VIC,WA</recruitmentstate>
    <hospital>Hornsby Ku-ring-gai Hospital; Division of Rehabilitation &amp; Aged Care - Hornsby</hospital>
    <hospital>Royal Adelaide Hospital; Memory Trials Centre - Adelaide</hospital>
    <hospital>The Queen Elizabeth Hospital; Neurology - Woodville</hospital>
    <hospital>Heidelberg Repatriation Hospital; Medical and Cognitive Research Centre - Heidelberg West</hospital>
    <hospital>The McCusker Alzheimer's Research Founation - Nedlands</hospital>
    <postcode>2077 - Hornsby</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>5011 - Woodville</postcode>
    <postcode>3081 - Heidelberg West</postcode>
    <postcode>6009 - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Rhode Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Ciudad Autonoma de Bs As</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Santa Fé</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Sofia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Varna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Nova Scotia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Aarhus C</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Copenhagen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Kuopio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Turku</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bordeaux</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Bron</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Limoges</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Marseille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Rennes</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>St Herblain</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Strasbourg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Göttingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Leipzig</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Mittweida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>München</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Ulm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Westerstede</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Guatemala</country>
      <state>Ciudad de Guatemala</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Guatemala</country>
      <state>Ciudad de Guatemlala</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Szzeged</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Emilia-Romagna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lazio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lombardia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Toscana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Chiba</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Fukuoka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Gunma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Hiroshima</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Hyogo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kanagawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Kyoto</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Nagasaki</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Niigata</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Oita</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Okayama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Osaka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Shizuoka</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Busan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Gyeonggi-do</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Incheon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Amadora</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Lisboa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Kazan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Saint Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Saratov</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>St Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>St. Petersburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Alicante</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Guipuzcoa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Vizcaya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sevilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Malmoe</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Stockholm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Basel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Lausanne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Antalya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Eskisehir</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Istanbul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Izmir</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Kocaeli</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Samsun</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Crowborough</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Preston</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Sheffield</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Southampton</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Swindon</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Hoffmann-La Roche</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Part 1 is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study
      will evaluate the efficacy and safety of gantenerumab in participants with mild Alzheimer
      disease. Participants will be randomized to receive either gantenerumab subcutaneously every
      4 weeks or placebo subcutaneously every 4 weeks. Approved Alzheimer medication is allowed if
      on stable dose for 3 months prior to screening. Part 2 is an open-label extension (OLE).

      A positron emission tomography (PET) imaging substudy will be conducted within the main
      study. Eligible participants who provide separate informed consent will undergo PET imaging
      scans using the radioligand florbetapir as a pharmacodynamic measure of changes in brain
      amyloid load over time. The substudy's target sample size is 100 participants in each arm of
      the main study.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02051608</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trials</name>
      <address>Hoffmann-La Roche</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>